By Mill Chart
Last update: Oct 9, 2023
Consider PFIZER INC (NYSE:PFE) as a top pick for dividend investors, identified by our stock screening tool. NYSE:PFE shines in terms of profitability, solvency, and liquidity, all while paying a decent dividend. Let's dive deeper into the analysis.
ChartMill assigns a Dividend Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing various dividend elements, such as yield, historical performance, dividend growth, and sustainability. NYSE:PFE has been awarded a 8 for its dividend quality:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NYSE:PFE has earned a 5 out of 10:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NYSE:PFE has earned a 8 out of 10:
More Best Dividend stocks can be found in our Best Dividend screener.
Check the latest full fundamental report of PFE for a complete fundamental analysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
PFIZER INC
NYSE:PFE (4/26/2024, 7:09:35 PM)
After market: 25.45 +0.05 (+0.2%)25.4
+0.14 (+0.55%)
Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
You'll get dividends and more with these great stocks.
Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.
CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.
Put your money to work by investing in these three high-quality dividend stocks.
Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.
The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.